AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3048364 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 asthmatic children)
Number of subjects: 21
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's involvement in antenatal care services
Number of subjects: 966
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint decision making on seeking antenatal care
Number of subjects: 966
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Accompaniment to antenatal clinic
Number of subjects: 966
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with healthcare providers
Number of subjects: 966
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical support during antenatal period
Number of subjects: 966
Study 31072322 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing involvement
Number of subjects: 966
Study 30211666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-outcome message
Number of subjects: 0
Study 30211666 — intervention group
Group type: COMPARATOR
Intervention: No message
Number of subjects: 0
Study 26879374 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily
Number of subjects: 214
Study 26879374 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone 5 mg twice daily
Number of subjects: 214
Study 24461175 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary treatment group (n=63)
Number of subjects: 117
Study 24461175 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=54)
Number of subjects: 117
Study 22982269 — intervention group
Group type: EXPERIMENTAL
Intervention: Habituation to pictures of objects in groups of two or three (intervention)
Number of subjects: 3
Study 19473192 — intervention group
Group type: EXPERIMENTAL
Intervention: gluten-free diet plus 6 mg budesonide daily
Number of subjects: 20
Study 19473192 — intervention group
Group type: COMPARATOR
Intervention: gluten-free diet alone
Number of subjects: 20
Study 19473192 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide (10-30 microg/mL) in vitro
Number of subjects: 20
Study 19473192 — intervention group
Group type: COMPARATOR
Intervention: gliadin alone
Number of subjects: 20
Study 17467265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 206
Study 17467265 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 206
Study 15692317 — intervention group
Group type: COMPARATOR
Intervention: PLAC (0.3 g.kg(‐1) body mass CaCO3 + 1 g NaCl)
Number of subjects: 8
Study 15692317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3CIT (0.3 g.kg(‐1) body mass tri-sodium citrate)
Number of subjects: 8
Study 15692317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5CIT (0.5 g.kg(‐1) body mass tri-sodium citrate)
Number of subjects: 8
Study 12475454 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454
Study 12475454 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 454
Study 9745228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) followed by sulbactam/cefoperazone (SBT/CPZ)
Number of subjects: 115
Study 9745228 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam/cefoperazone (SBT/CPZ) administered simultaneously with fosfomycin (FOM)
Number of subjects: 115
Study 8539545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 236
Study 8539545 — intervention group
Group type: COMPARATOR
Intervention: PcV
Number of subjects: 236
Study 2116206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold thiomalate
Number of subjects: 82
Study 2116206 — intervention group
Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 82
Study 2116206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 678739 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape feedback of the interview
Number of subjects: 0
Study 678739 — intervention group
Group type: COMPARATOR
Intervention: Videotape of another person being interviewed
Number of subjects: 0
Study 678739 — intervention group
Group type: COMPARATOR
Intervention: Engaged in other activities not involving videotape
Number of subjects: 0
Study 30998813 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel plus gemcitabine-cisplatin
Number of subjects: 62
Study 30998813 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-cisplatin alone (historical control)
Number of subjects: 62
Study 27175565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) with active recovery (50% of peak power output)
Number of subjects: 18
Study 27175565 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Exercise (HIIE) with passive recovery (A and C)
Number of subjects: 18
Study 27175565 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Exercise (HIIE) protocol C (90 seconds with passive recovery)
Number of subjects: 18
Study 25033263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent walking exercise (WE) - 15 × 2‐min bouts of WE with 2‐min rest intervals
Number of subjects: 20
Study 25033263 — intervention group
Group type: COMPARATOR
Intervention: Control (standing rest on a treadmill for 60 min)
Number of subjects: 20
Study 23395546 — intervention group
Group type: EXPERIMENTAL
Intervention: 840 mg/day DHA and 270 mg/day EPA from fish oil capsules
Number of subjects: 263
Study 23395546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 263
Study 21086216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 66
Study 21086216 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-experiential emotion-focused therapy
Number of subjects: 66
Study 19474689 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline incision
Number of subjects: 200
Study 19474689 — intervention group
Group type: COMPARATOR
Intervention: Transverse incision
Number of subjects: 200
Study 17094744 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced IV hydration with 2 L of normal saline over 2 hours
Number of subjects: 43
Study 17094744 — intervention group
Group type: COMPARATOR
Intervention: Minimal IV hydration at 20 mL of normal saline per hour
Number of subjects: 43
Study 15636426 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day for 4 months
Number of subjects: 20
Study 15636426 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 20
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, administered for 5 years
Number of subjects: 0
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation
Number of subjects: 0
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent chemotherapy of 4-6 months duration
Number of subjects: 0
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens
Number of subjects: 0
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0
Study 11791121 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy to the regional lymph nodes and chest wall following mastectomy
Number of subjects: 0
Study 11791121 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 9164883 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD patients
Number of subjects: 54
Study 9164883 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 54
Study 9164883 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 54
Study 9164883 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (night vs day)
Number of subjects: 54
Study 9164883 — intervention group
Group type: COMPARATOR
Intervention: Control patients (night vs day)
Number of subjects: 54
Study 9164883 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD patients (night vs day)
Number of subjects: 54
Study 7953984 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU of intranasal salmon calcitonin (sCT)
Number of subjects: 134
Study 7953984 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of intranasal salmon calcitonin (sCT)
Number of subjects: 134
Study 7953984 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of intranasal salmon calcitonin (sCT)
Number of subjects: 134
Study 7953984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 7953984 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU and 400 IU of intranasal salmon calcitonin (sCT) pooled
Number of subjects: 134
Study 3699218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate combined with dithranol and UVB
Number of subjects: 50
Study 3699218 — intervention group
Group type: COMPARATOR
Intervention: Dithranol and UVB alone
Number of subjects: 50
Study 31863962 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of bisphosphonate pamidronate within the first ten days of burn injury
Number of subjects: 0
Study 31863962 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of bisphosphonate pamidronate
Number of subjects: 0
Study 31863962 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum from patients given single dose bisphosphonate
Number of subjects: 0
Study 31863962 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum from bisphosphonate treated patients
Number of subjects: 0
Study 31863962 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody to transforming growth factor beta (TGFβ)
Number of subjects: 0
Study 29741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with weekly carboplatin (AUC 2) and paclitaxel (135 mg/m2), plus daily lapatinib (1000 mg) for 6 weeks followed by surgical resection.
Number of subjects: 40
Study 29741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with weekly carboplatin and paclitaxel, plus daily lapatinib followed by surgical resection.
Number of subjects: 40
Study 29741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and surgical resection followed by risk-adapted adjuvant therapy.
Number of subjects: 40
Study 29741773 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery following induction chemotherapy.
Number of subjects: 40
Study 27568126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile cognitive cardiac surgical simulator
Number of subjects: 16
Study 27568126 — intervention group
Group type: COMPARATOR
Intervention: Traditional reading-based self-study
Number of subjects: 16
Study 24990099 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAd5 injection
Number of subjects: 299
Study 24990099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gene therapy)
Number of subjects: 299
Study 22586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright, sideways, or horizontal repositioning maneuvers
Number of subjects: 1
Study 22586212 — intervention group
Group type: COMPARATOR
Intervention: Sleeping 1-year-olds of smokers
Number of subjects: 1
Study 15947713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (LSD)
Number of subjects: 24
Study 15947713 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal salt diet (NSD)
Number of subjects: 24
Study 15947713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (HSD)
Number of subjects: 24
Study 12426859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-adrenoceptor antagonists (alfuzosin, doxazosin, tamsulosin, terazosin)
Number of subjects: 14924
Study 12426859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 14924
Study 12426859 — intervention group
Group type: COMPARATOR
Intervention: Alpha1-adrenoceptor antagonists
Number of subjects: 14924
Study 12426859 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin or terazosin
Number of subjects: 14924
Study 12426859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-blockers
Number of subjects: 14924
Study 10199336 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin sympathetic nerve activity (SSNA) reflex latency in patients with cerebellar cortical atrophy
Number of subjects: 12
Study 10199336 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin sympathetic nerve activity (SSNA) reflex latency in patients with olivopontocerebellar atrophy
Number of subjects: 12
Study 10199336 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin sympathetic nerve activity (SSNA) in patients with Shy-Drager syndrome
Number of subjects: 12
Study 10199336 — intervention group
Group type: COMPARATOR
Intervention: Skin sympathetic nerve activity (SSNA) reflex latency in healthy controls
Number of subjects: 12
Study 8537548 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human tissue plasminogen activator (rhtPA: 10 mg)
Number of subjects: 14
Study 8537548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1691406 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril, 5 mg twice daily (b.i.d.)
Number of subjects: 225
Study 1691406 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril, 10 mg b.i.d.
Number of subjects: 225
Study 1691406 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril, 20 mg b.i.d.
Number of subjects: 225
Study 1691406 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril (dosage titrated to a maximum of 40 mg/day, 20 mg b.i.d.)
Number of subjects: 225
Study 1691406 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study 531231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 23
Study 531231 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 23
Study 31270177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 29
Study 31270177 — intervention group
Group type: COMPARATOR
Intervention: Standard Oxygen Therapy (standard O2)
Number of subjects: 29
Study 29704540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component kindergarten-based intervention to promote healthy diets and reduce food neophobia.
Number of subjects: 15
Study 28676443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Depressor (TD)
Number of subjects: 150
Study 26181716 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (video consultation)
Number of subjects: 73
Study 26181716 — intervention group
Group type: COMPARATOR
Intervention: Reference group (face-to-face consultation)
Number of subjects: 73
Study 24173259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 24173259 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 30
Study 24173259 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 30
Study 21195289 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA) at HT7
Number of subjects: 29
Study 21195289 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA) at LI10
Number of subjects: 29
Study 18410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 48
Study 18410297 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day for the first week, then 40 mg/day for the following 3 weeks)
Number of subjects: 48
Study 18410297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16952654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (100% O2 at 2.4 atmosphere absolute for 30 sessions)
Number of subjects: 21
Study 16952654 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (1.3 atmosphere absolute, breathing normal air)
Number of subjects: 21
Study 12878284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena
Number of subjects: 438
Study 12878284 — intervention group
Group type: COMPARATOR
Intervention: NovaT
Number of subjects: 438
Study 11125653 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia form administered by computer
Number of subjects: 0
Study 11125653 — intervention group
Group type: COMPARATOR
Intervention: Written form administered by computer (computerized page-turner)
Number of subjects: 0
Study 11125653 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil form
Number of subjects: 0
Study 9177067 — intervention group
Group type: EXPERIMENTAL
Intervention: CPN aftercare for 1 year
Number of subjects: 127
Study 9177067 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 127
Study 1530169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping with adhesive tape
Number of subjects: 21
Study 1530169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning with benzine
Number of subjects: 21
Study 1530169 — intervention group
Group type: COMPARATOR
Intervention: Scrubbing with Skin‐Pure jelly
Number of subjects: 21
Study 3884426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (0.3 g/day in 2 oral doses)
Number of subjects: 354
Study 3884426 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1.6 g/day in 4 oral doses)
Number of subjects: 354
Study 3884426 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 354
Study 3884426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 354
Study 30089732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (30-minute ice pack application each day for 10 days)
Number of subjects: 0
Study 30089732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (β3 receptor agonist, 50 mg/day for 10 weeks)
Number of subjects: 0
Study 27282232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud-based BP system integrated with CPOE
Number of subjects: 382
Study 27282232 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 382
Study 24576907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose (2D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,6
Number of subjects: 479
Study 24576907 — intervention group
Group type: COMPARATOR
Intervention: 3-dose (3D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,1,6
Number of subjects: 479
Study 24576907 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose (2D) schedule
Number of subjects: 479
Study 24576907 — intervention group
Group type: COMPARATOR
Intervention: 3-dose (3D) schedule
Number of subjects: 479
Study 24576907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2D and 3D schedules
Number of subjects: 479
Study 22348812 — intervention group
Group type: COMPARATOR
Intervention: Air with constant flow (1.5 L/min)
Number of subjects: 10
Study 22348812 — intervention group
Group type: COMPARATOR
Intervention: Oxygen with constant flow (1.5 L/min)
Number of subjects: 10
Study 22348812 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen flow titration
Number of subjects: 10
Study 20080288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of periprostatic anesthesia and bilateral pudendal block (group 2)
Number of subjects: 150
Study 20080288 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic anesthesia only (group 1)
Number of subjects: 150
Study 20080288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 18545185 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric exercise of quadriceps femoris
Number of subjects: 24
Study 18545185 — intervention group
Group type: COMPARATOR
Intervention: Resting group
Number of subjects: 24
Study 15960148 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 73
Study 15960148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12885708 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified fish sauce (10 g with 5 mg Fe)
Number of subjects: 50
Study 12885708 — intervention group
Group type: COMPARATOR
Intervention: FeSO4-fortified fish sauce (10 g with 5 mg Fe)
Number of subjects: 50
Study 12885708 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified soy sauce (10 g with 5 mg Fe)
Number of subjects: 50
Study 12885708 — intervention group
Group type: COMPARATOR
Intervention: FeSO4-fortified soy sauce (10 g with 5 mg Fe)
Number of subjects: 50
Study 12885708 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified fish sauce vs soy sauce
Number of subjects: 50
Study 12885708 — intervention group
Group type: COMPARATOR
Intervention: Soy sauce effect on rice-based meals
Number of subjects: 50
Study 12885708 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish sauce effect on iron absorption
Number of subjects: 50
Study 10593384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification of mouse blastocysts
Number of subjects: 0
Study 10593384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification of human blastocysts
Number of subjects: 0
Study 10593384 — intervention group
Group type: COMPARATOR
Intervention: Nonfrozen blastocysts
Number of subjects: 0
Study 8733742 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased SPL activation
Number of subjects: 16
Study 8733742 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased difficulty in information processing
Number of subjects: 16
Study 1770152 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose: 5.0 ± 2.3 mg)
Number of subjects: 29
Study 1770152 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (mean daily dose: 182.0 ± 60.5 mg)
Number of subjects: 29
Study 6755764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penbutolol
Number of subjects: 12
Study 6755764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31791303 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation in addition to routine inpatient care for 6 months after discharge.
Number of subjects: 144
Study 31791303 — intervention group
Group type: COMPARATOR
Intervention: Routine inpatient care without psychosocial stimulation and home-based follow up for 6 months after discharge.
Number of subjects: 144
Study 28698319 — intervention group
Group type: EXPERIMENTAL
Intervention: sPATH intervention (five postdischarge motivational interviewing sessions, face to face or by phone)
Number of subjects: 290
Study 28698319 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 290